新西兰因轮状病毒胃肠炎住院:实验室数据库是评估轮状病毒疫苗接种效果的有价值工具
该研究利用惠灵顿和赫特医院2010年1月1日至2016年12月31日的回顾性实验室轮状病毒检测数据及全国编码住院数据,评估新西兰引入轮状病毒疫苗的影响。结果显示,疫苗接种后(2015-2016年)当地确诊轮状病毒胃肠炎住院减少94.6%,仅8例确诊,胃肠炎总住院下降51.4%;全国编码轮状病毒住院较接种前平均值低87.1%。结论认为疫苗接种显著减少住院,全国数据可能低估疫苗影响。
要点
- 接种后2015-2016年当地确诊轮状病毒胃肠炎住院减少94.6%,仅8例确诊。
- 同期当地胃肠炎总住院下降51.4%,全国胃肠炎年均住院下降34.4%。
- 全国编码轮状病毒住院较接种前平均值低87.1%,可能低估疫苗影响。
核心结论
- 轮状病毒疫苗接种在引入后两年内显著减少了新西兰的胃肠炎住院人数,全国数据可能低估疫苗影响。
研究设计与样本
- 回顾性实验室数据研究,纳入惠灵顿和赫特医院2010年1月1日至2016年12月31日的轮状病毒检测数据,并与5岁以下儿童胃肠炎主要和次要编码住院数据匹配;第二部分分析同期全国主要编码胃肠炎住院数据集。
主要发现
- 惠灵顿和赫特医院1645例胃肠炎住院中,1054例(64.1%)进行了轮状病毒检测,其中409例(38.8%)阳性。
- 未以胃肠炎为主要编码的儿童占轮状病毒住院的5.7%。
- 接种前惠灵顿和赫特地区5岁以下儿童估计年轮状病毒住院率为每10万人427.1例。
- 接种后(2015-2016年)确诊轮状病毒胃肠炎住院减少94.6%,仅8例确诊;胃肠炎总住院下降51.4%。
- 全国范围胃肠炎年均住院数下降34.4%,编码轮状病毒住院数较接种前平均值低87.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess the impact of the introduction of rotavirus vaccination in New Zealand at a regional and national level, underlining the utility of a passively collected laboratory dataset. METHOD: Retrospective laboratory data for rotavirus testing from Wellington and Hutt Hospitals from 1 January 2010 to 31 December 2016, matched with hospital admissions data of children under 5years of age with gastroenteritis primary and secondary coded admissions. The second part of the study examined the national dataset of primary coded hospital gastroenteritis admissions from the same period. RESULTS: Rotavirus testing was performed in 1054 (64.1%) of the 1645 gastroenteritis admissions to Wellington and Hutt Hospitals. Four hundred and nine of these tests (38.8%) were positive. Children who were not given a primary code of gastroenteritis accounted for 5.7% of rotavirus admissions. The estimated annual rotavirus hospitalisation rate in the Hutt and Wellington regions for children under 5years during the pre-vaccination period was 427.1 per 100,000. In the post-vaccination period (2015-2016), there was a 94.6% reduction in confirmed rotavirus gastroenteritis hospitalisations with only 8 confirmed cases. The total number of gastroenteritis admissions declined by 51.4%. On a national scale, there was a decline of 34.4% in the average annual number of gastroenteritis admissions and the number of coded rotavirus admissions was 87.1% lower than the pre-vaccination average. CONCLUSION: The non-restrictive continuous approach to rotavirus testing has provided a detailed description of the epidemiology of rotavirus gastroenteritis hospitalisations in the Wellington and Hutt regions. Rotavirus vaccination introduced on the crest of a peak in rotavirus cases has lead to a marked reduction in the number of admissions with gastroenteritis in New Zealand in the two years following vaccine introduction. The national figures likely underestimate the impact of the vaccine.
引用
- Kelly MJ, Foley D, Blackmore TK, et al. Hospitalised rotavirus gastroenteritis in New Zealand: The laboratory database is a valuable tool for assessing the impact of rotavirus vaccination. Vaccine. 2017. PMID: 28720280. doi:10.1016/j.vaccine.2017.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。